Melinda Brown Net Worth

The estimated Net Worth of Melinda Brown is at least $385 Thousand dollars as of 4 May 2024. Melinda Brown owns over 4,202 units of Precision BioSciences stock worth over $44,121 and over the last 8 years Melinda sold DTIL stock worth over $340,560.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Melinda Brown DTIL stock SEC Form 4 insiders trading

Melinda has made over 2 trades of the Precision BioSciences stock since 2017, according to the Form 4 filled with the SEC. Most recently Melinda exercised 4,202 units of DTIL stock worth $44,121 on 4 May 2024.

The largest trade Melinda's ever made was selling 8,250 units of Precision BioSciences stock on 12 September 2017 worth over $340,560. On average, Melinda trades about 1,038 units every 202 days since 2016. As of 4 May 2024 Melinda still owns at least 4,202 units of Precision BioSciences stock.

You can see the complete history of Melinda Brown stock trades at the bottom of the page.

What's Melinda Brown's mailing address?

Melinda's mailing address filed with the SEC is C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM, NC, 27701.

Insiders trading at Precision BioSciences

Over the last 6 years, insiders at Precision BioSciences have traded over $352,500 worth of Precision BioSciences stock and bought 224,670 units worth $1,909,002 . The most active insiders traders include Raymond F Schinazi, Llc Fmr, and Michael Amoroso. On average, Precision BioSciences executives and independent directors trade stock every 22 days with the average trade being worth of $357,735. The most recent stock trade was executed by Dario Scimeca on 7 June 2024, trading 301 units of DTIL stock currently worth $3,161.

What does Precision BioSciences do?

Precision BioSciences, Inc., a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Complete history of Melinda Brown stock trades at Tapestry Inc and Precision BioSciences

Precision BioSciences executives and stock owners

Precision BioSciences executives and other stock owners filed with the SEC include:

• Michael Amoroso,
  Pres, CEO & Director
• Matthew R. Kane,
  Advisor
• Dr. Christopher R. Heery,
  Consultant
• Dora Alvarado,
  Sr. VP of Human Resource
• Maurissa Messier,
  Sr. Director of Corp. Communications
• Heather King,
  Director of Marketing Communications & PR
• Bruce Stevens,
  VP of Quality & Compliance
• Dr. Derek Jantz Ph.D.,
  Co-Founder, Chief Scientific Officer & Director
• Shane Barton,
  VP, Corp. Controller & Principal Accounting Officer
• Dr. David S. Thomson Ph.D.,
  Chief Operating Officer
• John Alexander Kelly,
  Chief Financial Officer
• Dr. Jefferson J. Smith Ph.D.,
  Co-Founder & CTO
• Dario Scimeca,
  Gen. Counsel & Sec.
• Shari Lisa Pire,
  
• Samuel C. Wadsworth,
  
• Stanley Frankel,
  
• Kevin Buehler,
  
• Shane Barton,
  VP & Corporate Controller
• Fayaz Khazi,
  CEO of Elo Life Systems
• Raymond F Schinazi,
  Director
• Matthew R. Kane,
  President and CEO
• Abid Ansari,
  Chief Financial Officer
• Christopher Heery,
  Chief Medical Officer
• Shalini Sharp,
  Director
• Geno J Germano,
  
• Tony Dung Ling Yao,
  Director
• Llc Fmr,
  
• Derek Jantz,
  Chief Scientific Officer
• Global Strategic Fund, L.P....,
  
• David S. Thomson,
  Chief Operating Officer
• Michael Amoroso,
  President and CEO
• Melinda Brown,
  
• J. Jefferson Smith,
  Chief Research Officer
• Dario Scimeca,
  General Counsel and Secretary
• John Alexander Kelly,
  Chief Financial Officer
• Alan List,
  Chief Medical Officer